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AbstRACt
background: Uterine fibroids are responsible for significant morbidity in a large proportion of the female population of the 
reproductive age worldwide. Hence, there is a need to determine the levels of oestrogen and progesterone receptors in 
relation to the growth and symptomatology in a purely African population noted for high incidence of uterine fibroids.
Objectives: To determine the levels of oestrogen and progesterone receptors in normal myometrium and uterine fibroids 
and ascertain whether there are any significant clinical associations.
Materials and Methods: This was a prospective study conducted at the Obstetrics and Gynaecology Department in 
collaboration with the Morbid Anatomy Department, both at the University of Benin Teaching Hospital (UBTH). Tissue 
specimens obtained from uterine fibroids and normal myometrium during surgeries performed on patients with a pre‑operative 
diagnosis of uterine fibroids were histologically examined. The concentrations of oestrogen and progesterone receptors 
were histochemically determined for the selective tissue slides. The results and the socio‑demographic characteristics of 
the patients were used to generate a database for analysis.
Results: A total of 262 cases of uterine fibroids were analysed. Those presenting with lower abdominal mass had more oestrogen 
receptors in uterine fibroids (57.0%, P = 0.014), whereas more progesterone receptors were found in those presenting with 
menorrhagia (P = 0.001). A comparison of oestrogen and progesterone receptors in uterine fibroids and normal myometrium 
showed significantly higher levels of oestrogen and progesterone receptors in fibroids than in normal myometrium (P = 0.000).
Conclusion: The concentrations of oestrogen and progesterone receptors in uterine fibroids were significantly higher than 
those in normal myometrium. The steroid dependence of the growth and symptomatology of uterine fibroids may be related 
to the steroid receptor level. Identification and quantification of the concentrations of oestrogen and progesterone receptors 
will be useful in the prognostication and the development of newer treatment modalities for uterine fibroids. Further research 
in this area is clearly warranted.
Key words: Myometrial tissues; oestrogen receptors; progesterone receptors; uterine fibroids; University of Benin Teaching 
Hospital.
Introduction
Uterine fibroids, also known as uterine leiomyoma, is a 
benign tumour of the uterus composed of smooth muscles 
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and varying amounts of connective tissue.[1] It is the most 
common tumour of the uterus among women of reproductive 
age.[1,2] Uterine fibroids are seen in approximately 20–25% of 
women of reproductive age.[3] Autopsy studies have shown 
higher incidences of uterine fibroids of various sizes and 
shapes, though many were asymptomatic.[1] They frequently 
cause serious gynaecological problems such as pelvic pain, 
menorrhagia, dysmenorrhoea, reduced fertility and recurrent 
pregnancy loss.[4,5] In addition, uterine fibroids is the most 
common indication for hysterectomy all over the world, 
especially in Nigeria.[6,7]
The pathophysiology of uterine fibroids has not been explored 
satisfactorily despite the high prevalence rate and tremendous 
influence on women during their reproductive years.[1-3,8,9] 
The relationships between cytogenetic changes of individual 
fibroids and hormonal mechanisms are not very clear.[3,8,9] 
There are reasons to believe that somatic mutations induce 
changes in the myometrial cell clones resulting in a progressive 
loss of growth regulation.[3,8,9] Further development of 
the tumour is steroid hormone dependent and the main 
hormones implicated are oestradiol and progestogens, with 
the population of receptors to these hormones increased in 
uterine fibroids.[3,9] This is supported by the observation that 
generally fibroids do not occur before the menarche and they 
shrink markedly after the menopause.[1,2,5,8,10] Although the 
increased sensitivity to oestradiol is important for the growth 
of uterine leiomyomas, high circulating oestradiol levels are 
not a necessary requirement.[2]
The physiological effects of oestrogen are mediated by 
oestrogen receptors (ERs), among them, ER is more highly 
expressed in uterine leiomyomas than in normal myometrium 
suggesting a possible link between uterine leiomyomas and 
ER-expression level.[8,9] In past, oestrogen was considered to 
play an important role in the growth of uterine fibroids. Later 
studies have shown that there is an increased concentration 
of progesterone receptors (PR) in leiomyoma tissue than the 
normal myometrium.[3,8,9] Accumulating evidence indicates 
that the effects of steroid hormones on the growth of fibroids 
are mediated by specific genes coding for growth factors 
and their receptors, either directly or via steroid-responsive 
transcription factors, which consist of protein products of 
cell cycle-related genes.[1] The steroid hormone/receptor 
complex in itself may function as a transcription factor, 
binding to elements that are located in the promoter region 
of steroid-responsive genes.[9] Most fibroids grow slowly and 
the mechanisms responsible for their neoplastic potential are 
not completely known.
Recently, increasing interest has been directed towards 
pharmacological treatment of fibroids, although these are 
for symptomatic relief and not for cure.[9] Two randomised 
controlled trials have shown that progestins, when used 
as add-back therapy in combination with gonadotrophin 
releasing hormones (GnRH) agonists, attenuate or reverse the 
inhibitory effects of GnRH agonists on uterine fibroids.[10,11]
Worldwide, uterine fibroids are responsible for significant 
morbidity in a large proportion of the female population of 
reproductive age. Studies from developed countries have 
established high levels of ER and PR expression in uterine 
fibroids than in normal myometrium of women.[3,9,10]
This study was undertaken to compare the concentrations 
of ER and PR in fibroids and normal myometrium obtained 
during surgery and to determine the clinical significance.
Materials and Methods
This was a prospective study conducted at the Department of 
Obstetrics and Gynaecology and the Immunohistochemistry 
unit of the Department of Morbid Anatomy, University of 
Benin Teaching Hospital, Benin-City, Nigeria. The sample 
size was determined using the formula by Taylor based on 
the prevalence of about 25%. The calculated sample size was 
288 patients.[3,5,12]
Tissue specimens obtained from surgeries performed 
on patients with a pre-operative diagnosis of uterine 
fibroids from 1st January 2009 to 31st December 2009 were 
histologically examined. Tissue specimens from both the 
uterine fibroids and normal myometrial tissues from the same 
patients were taken for analysis. A semi-qualitative analysis 
of ER and PR, where the number of receptors that took up 
stain were quantified, was done.
The tissues were fixed immediately in 10% normal saline 
for 24 hours, following which good representative sections 
were obtained and placed in tissue pre-labeled cassettes 
for processing. The tissue processing involved the use of 
automatic tissue processor (LEICA TP 1020) and entailed 
dehydration in 70% alcohol.
The tissues were then transferred into toluene bath 1 
for 2 hours and toluene bath 2 for 2 hours. Thereafter, 
wax impregnation of the tissues was carried out in 
thermostatically controlled molten wax for 2 hours. The 
tissues were then taken through the process of blocking 
out, trimming and sectioning. The sections were made at 
3-micrometer guage and then floated on water, in a water 
bath, while the sections were picked with pre-labelled 
APEC-coated slides. The sections were well drained and 
heated at 60°C for about an hour on a hot plate. The samples 
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were then subjected to immunohistochemistry procedure 
using Novolink.
The results were recorded on data sheets and analysis was 
done with personal computer using the Statistical Package 
for Social Sciences version 20.0 (SPSS IBM Corp, Armonk, 
NY) and GraphPad Instat 3 software, (GraphPad Software Inc., 
San Diego, CA) with P value of <0.05 level of significance at 
95% confidence internal.
Results
A total of 288 tissue specimens were collected from fibroids 
and paired with the same number from normal myometrium. 
Of the 288 tissue specimens, 262 were found to be adequate 
for analysis and therefore formed the basis of this study.
The mean ± SD age of the patients was 35.98 ± 5.93 years. 
The mean parity ± SD was 1.12 ± 1.87. Most of the patients 
presented within the age range of 35–39 years (29.40%) 
and >40 years (29.80%). Uterine fibroids were seen more 
among nulliparous patients (61.80%), and the incidence 
reduces with increase in parity [Table 1]. Most of the 
patients (172; 65.6%) presented with lower abdominal mass, 
whereas 143 (54.6%) presented with menorrhagia. Thus, 
menorrhagia and lower abdominal mass were the common 
presenting symptoms. Fifty-seven patients (21.76%) had more 
than one clinical feature at presentation.
When clinical features were compared with the quantity 
of ERs as suggested by the degree of slides staining, it was 
observed that most were mildly stained in patients with 
menorrhagia, lower abdominal pains and pressure symptoms. 
None of the slides were deeply stained and only small 
fractions were moderately stained for ERs [Table 2].
When the clinical features were compared for quantity of 
PRs, all the 3 clinical features considered had varying degrees 
of specimen staining for PRs. Menorrhagia was associated 
with more progesterone receptors in the uterine fibroids, 
with a P value of 0.001 which was statistically significant 
[Table 2].
When the tissue specimens stained for ERs and PRs were 
compared between the histological samples, it was observed 
that 172 (65.6%) slides from uterine fibroids took some 
stain (mildly or moderately stained) for oestrogen compared 
to 65 (24.8%) for the normal myometrial tissues [Table 3].
For progesterone receptors, 220 (84%) of the slides from 
uterine fibroids had various degrees of staining compared 
to only 129 (49.20%) from normal myometrium. While 
only 42 (16.0%) of uterine fibroid slides did not show any 
form of staining, 138 (50.80%) from normal myometrium 

















Lower abdominal mass 172 65.60
Pressure symptoms (Urinary frequency) 40 15.30
Total ** **
**Multiple responses were obtained as presenting symptoms, as most patients had 
more than one symptom at presentations
Table 2: Clinical symptoms compared with the concentrations 
of progesterone and estrogen receptors in uterine fibroids
Receptor concentration 
(−, +, ++, +++)
P
Progesterone receptors
Menorrhagia 24 (16.8%) 53 (37.1%) 35 (24.5%) 31 (21.7%) 0.010
Lower abdominal mass 26 (15.1%) 47 (27.3%) 67 (39.8%) 32 (18.6%) 0.074
Pressure symptoms 8 (20.8%) 11 (27.5%) 12 (30.8%) 9 (22.5%) 0.603
Oestrogen receptors
Menorrhagia 47 (32.9%) 88 (61.5%) 8 (5.6%) 0 (0.0%) 0.840
Lower abdominal mass 59 (34.3%) 98 (57.0%) 15 (8.78%) 0 (0.00%) 0.014
Pressure symptoms 17 (42.5%) 23 (57.5%) 0 (0.00%) 0 (0.00%) 0.160
− - Not stained; + - Mildly stained; ++ - Moderately stained; +++ - Deeply stained
Table 3: Comparison of progesterone and oestrogen receptors 









− 133 50.8 42 16.0
+ 91 34.7 84 32.1
++ 38 14.5 91 34.7
+++ 0 0.0 45 17.2
Total 262 100 262 100
Oestrogen receptors 0.000
− 197 75.2 90 34.4
+ 65 24.8 157 59.9
++ 0 0.0 15 5.7
+++ 0 0.0 0 0.0
Total 262 100 262 100
− - Not stained; + - Mildly stained; ++ - Moderately stained; +++ - Deeply stained
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did not [Table 3]. A comparism of the two groups showed 
statistical significant difference (P = 0.000).
Discussion
This study has further confirmed that uterine fibroids are 
common within the ages 25 and 40 years – the reproductive 
age of most women, as has been shown in other studies.[1,3] 
The results showed that 180 (68.70%) of the 262 patients 
studied were within the ages of 25 and 39 years. This confirms 
the common occurrence of uterine fibroids. Approximately 
two-thirds (61.80%) of our patients were nullipara, with 56.5% 
having between 1–4 miscarriages in consonance with the 
previous reports, associating uterine fibroids with nulliparity, 
reduced fertility and recurrent pregnancy losses.[4,5,11,13] 
Although most were asymptomatic, those presenting with 
symptoms had lower abdominal mass in 65.6% of cases, which 
was closely followed by menorrhagia 54.6%.
Findings from this study indicate a statistically significant 
association (P = 0.014) between the presence of ERs in 
uterine fibroids and the specific symptomatology of lower 
abdominal mass. Although increase in abdominal mass was 
seen in older patients in this study, it was discovered that 
increase in the size of the lower abdominal mass had no 
relationship with the degree of staining for ERs.
Several anti-oestrogen compounds have recently 
become available and useful for the medical treatment 
of symptomatic uterine fibroids.[7-9,14] This includes the 
use of selective ER modulators as well as the use of pure 
anti-oestrogens.[7-9,14,15] Drugs such as Luprorelin acetate 
depot, a gonadotrophin- releasing hormone (GnRH) agonist, 
which has been found to cause hypo-oestrogenism followed 
by the regression of uterine leiomyomas are also useful in 
the management of uterine leiomyomas.[8-10]
Patients presenting with menorrhagia had a high concentration 
of PRs in their uterine fibroids (P value of 0.001), which 
was highly statistically significant. This justifies the use 
of gonadotrophin-releasing hormone agonist in the 
management of patients with uterine fibroids presenting with 
irregular menstrual blood loss (menorrhagia) with consequent 
anaemia. They cause amenorrhoea with restoration of normal 
haemoglobin levels and significant reduction in the sizes of 
the uterine fibroids.[9,10] Anti-progesterone compounds seem 
promising, of value is the use of Mifepristone 25 mg per day 
for 6 months.[16,17] Treatment with mifepristone also induces 
regression of uterine leiomyomas.[16] This has been clearly 
demonstrated in this study with uterine fibroids having high 
levels of PRs.
Approximately a quarter (24.8%) of normal myometrial tissue 
slides were mildly stained for oestrogen receptors whereas 
about two third (59.9%) of uterine fibroids tissues were mildly 
and moderately stained (5.7%) with a cumulative percentage 
of 65.6%. This observation is consistent with earlier studies, 
majority of which have demonstrated that ERs and PRs are 
greater in fibroid than normal myometrium.[3,8,9,17]
The finding of greater staining for progesterone receptors 
in uterine fibroids (84.0%) as against that in normal 
myometrium (49.2%) in this study is at variance with other 
studies. Pollow et al. found fibroid steroid hormone receptor 
concentrations to be lower for PRs as against normal 
myometrium, however, the ER concentrations were more 
in the uterine fibroids compared to normal myometrium.[18] 
However, other studies lend credence to the findings in this 
study that both ER PR levels are higher in fibroid than normal 
myometrium.[3,8-10,17]
Otubu et al. found a significantly higher concentration 
of 17β-oestradiol in fibroids than normal myometrium, 
especially in the proliferative phase, whereas no difference 
in the concentration of progesterone was found.[19] The 
authors speculated that the higher levels of oestradiol in 
the fibroids could be related to lower levels of the enzyme 
17β-hydroxysteroid dehydrogenase, which accelerates the 
conversion of oestradiol to oestrone. Our study did not take 
into cognisance the phase of the cycle when the specimens 
were taken.
When the quantity of ERs in uterine fibroids were 
compared to that in normal myometrium, there was a 
statistically significantly higher concentration of receptors 
in fibroids than in normal myometrium (P = 0.000). On 
comparing the quantity of PRs in uterine fibroids and normal 
myometrium, it was significantly higher in the former than 
in the latter (P = 0.000). This agrees with the first report 
in literature by Sadan et al., which found that ERs and 
PRs in leiomyoma were significantly higher than in normal 
myometrium (P = 0.0002).[20] This study has demonstrated 
that the concentrations of ERs and PRs are greater in uterine 
fibroids than that in the normal myometrium and also that 
there is a relationship between ERs and PRs with the pattern 
of clinical presentation of uterine fibroids.
Uterine fibroids have a substantial impact on women’s 
reproductive health, they cause significant morbidity, 
including prolonged or heavy menstrual bleeding, pressure 
symptoms, pain and in rare cases, reproductive dysfunction 
particularly in our environment. Thus, both the economic 
cost and adverse effect on quality of life are substantial. 
Surgery remains the mainstay of fibroid treatment, and 
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various minimally invasive procedures have been developed 
in addition to hysterectomy and abdominal myomectomy, 
which have made little impact where we practice because of 
late presentation, ignorance and poverty.[5] Formation of new 
fibroid masses after these conservative therapies remains a 
significant challenge. Although medications that manipulate 
concentrations of steroid hormones are effective, their 
side-effects limit long-term use. A better approach would be 
the manipulation of the steroid-hormone milieu with specific 
hormone antagonists. There has been little evidence-based 
evaluation of therapy. Research into the basic biology of these 
neoplasms will continue to add new treatment options for 
the future as the role of growth factors and genetic mutations 
in these tumours are better understood.
The absence of tissue stain for ERs and PRs in some tissue 
samples from uterine fibroids sites requires further studies. 
Not considering the phase of the menstrual cycle at the 
time of specimen collection for this study is considered a 
limitation.
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